Two Trials of Therapeutics for MASH with Liver Fibrosis

MeSH terms

• Clinical Trials, Phase II as Topic
• Gastric Inhibitory Polypeptide* / administration & dosage
• Gastric Inhibitory Polypeptide* / adverse effects
• Gastric Inhibitory Polypeptide* / analogs & derivatives
• Glucagon-Like Peptide-1 Receptor Agonists* / administration & dosage
• Glucagon-Like Peptide-1 Receptor Agonists* / adverse effects
• Humans
• Liver Cirrhosis* / drug therapy
• Liver Cirrhosis* / etiology
• Liver Cirrhosis* / metabolism
• Non-alcoholic Fatty Liver Disease* / complications
• Non-alcoholic Fatty Liver Disease* / drug therapy
• Non-alcoholic Fatty Liver Disease* / metabolism
• Receptors, Gastrointestinal Hormone / agonists
• Receptors, Glucagon / agonists
• Tirzepatide
• Weight Loss / drug effects